- If Hillary Clinton Is Elected President, Here's What Will Happen to the U.S. Economy
- Hillary Clinton and Bernie Sanders Might Run for President Together
- Here's How Hillary Clinton's Email Scandal Could End Her White House Run
- Farmers To Gain Access To Monsanto's Roundup Ready 2 Xtend™ Soybeans In 2016
- Why Tesla Motors Is the Worst Stock in the World
Drug companies are under pressure in the short term, but in the long term, some of them look very attractive based on earnings potential, Jim Cramer said.
Jim Cramer says health care companies will be in the spotlight this week and investors should take a long-term view of the sector if stocks sell off.
Exelixis didn't provide specifics about the duration of Cometriq's survival benefit, so it's not known if the new data will help the company compete any better against Bristol-Myers Squibb.
Biotech news and observations to start the week.
The American Antitrust Institute has taken a stand against Israel-based Teva Pharmaceuticals' $40.5 billion deal to acquire the generics operation of Allergan.
San Francisco biopharmaceutical company KaloBios says the highly competitive nature of its industry makes bonus payments necessary to retain eight workers.
The list price for Merck's newly approved hepatitis C drug is lower than competing therapies from Gilead Sciences and Abbvie, which means a new price war could be heating up.
The World Health Organization said Thursday that the Zika virus is ‘spreading explosively’ in the Americas and that there is a high level of concern and uncertainty about the virus.
Amid this wildly volatile market, investors may want to turn to safe, conservative Big Pharma stocks that pay dividends. Which of these two drug giants is the better stock?
U.S. stocks were higher after a series of positive tech earnings from the likes of Facebook (FB) and PayPal (PYPL) boosted the Nasdaq.
Celldex will announce the outcome of an interim analysis for a pivotal study of its brain tumor therapy Rintega within weeks.
Earnings estimates for the biotechnology specialist have risen over the past three months, but its share price has fallen 15%. Sooner or later, the market should realize its mistake.
In 'What's Ahead on Wall Street' for Thursday January 28, there are lots of earnings on tap but TheStreet highlights a few major ones.
Stocks remained lower as poor earnings reports from industry giants Apple (AAPL) and Boeing (BA) punished the tech and industrials sectors.
The controversy over drug pricing factored into Biogen's revenue guidance for 2016.
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.